Ankit Mahadevia
2021
In 2021, Ankit Mahadevia earned a total compensation of $4.9M as Chief Executive Officer at Spero Therapeutics, a 130% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $327,618 |
|---|---|
| Option Awards | $2,650,765 |
| Salary | $590,417 |
| Stock Awards | $1,300,000 |
| Other | $6,245 |
| Total | $4,875,045 |
Mahadevia received $2.7M in option awards, accounting for 54% of the total pay in 2021.
Mahadevia also received $327.6K in non-equity incentive plan, $590.4K in salary, $1.3M in stock awards and $6.2K in other compensation.
Rankings
In 2021, Ankit Mahadevia's compensation ranked 2,701st out of 12,405 executives tracked by ExecPay. In other words, Mahadevia earned more than 78.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,701 out of 12,405 | 78th |
Division Manufacturing | 1,064 out of 5,494 | 81st |
Major group Chemicals And Allied Products | 416 out of 2,369 | 82nd |
Industry group Drugs | 363 out of 2,090 | 83rd |
Industry Pharmaceutical Preparations | 239 out of 1,537 | 85th |
Source: SEC filing on August 5, 2022.
Mahadevia's colleagues
We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2021.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019